INDIANA BUSINESS

Telix says first U.S. Pixclara doses given; press release datelined Indianapolis marks U.S. commercial start

Telix Pharmaceuticals announced on Oct. 6, 2026, that the first U.S. patients have been dosed with FDA‑approved Pixclara (floretyrosine F 18), and described the event as marking the start of U.S. commercial availability. The company’s release was datelined MELBOURNE and INDIANAPOLIS and named administering sites and a U.S. manufacturing and pharmacy distribution partner.

BUSINESSINDY BRIEFBy BusinessIndy Editorial StaffCommentsPublished October 7, 2026 at 8:32 AM EDTOriginal reporting: October 5, 2026 at 8:00 PM EDT · Brief prepared from earlier coverage

AI-generated illustration of the topic: Telix says first U.S. Pixclara doses given; press release datelined Indianapolis marks U.S. commercial start — AI illustration · Not a photograph of the reported event.

Telix Pharmaceuticals said in a press release dated Oct. 6, 2026, that the first patients in the United States have been dosed with Pixclara (floretyrosine F 18) and that the event marks the start of U.S. commercial availability. The release carried datelines MELBOURNE and INDIANAPOLIS and named administering sites and its U.S. manufacturing and pharmacy distribution partner.

Pixclara is described in the release as an FDA‑approved amino acid positron emission tomography (PET) drug for glioma imaging that comprises a small‑molecule targeting compound labeled with fluorine‑18. The company summarized safety data from 382 patients, reported mean dosing activity for adult and pediatric cohorts, listed common adverse reactions (including nausea, injection site reaction, fatigue, malaise and headache), and noted that Pixclara contributes to long‑term cumulative radiation exposure.

WHY IT MATTERS

What changed and who this affects: Telix’s announcement signals that Pixclara, an FDA‑approved PET imaging agent for glioma, is being used commercially in the U.S. A PET scan uses a tiny amount of a radioactive tracer and a specialized scanner to make images; Pixclara is a fluorine‑18–labeled molecule that, after intravenous injection, seeks out certain membrane transport proteins (called L‑type amino acid transporters 1 and 2, or LAT1 and LAT2). Once the tracer binds, the radioisotope emits energy that a PET scanner detects, helping physicians distinguish recurrent or progressive glioma from treatment‑related changes when used alongside other diagnostic tests.

Practical implications and safety: The release includes safety results from 382 patients and reports common adverse reactions such as nausea, injection‑site reaction, fatigue, malaise and headache. Telix also reminded readers that Pixclara adds to a patient’s long‑term cumulative radiation exposure and that such exposure is associated with increased cancer risk. The company provided guidance for reporting suspected adverse reactions to the FDA via MedWatch and supplied its contact details.

Next step to watch: Officials, imaging centers and clinicians will likely publish local availability and scheduling details; Telix’s named U.S. manufacturing and pharmacy distribution partner and any site‑level rollout plans are the next items to track for when and where patients can access commercial Pixclara.

Report a correction · Editorial standards · Our source directory

BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.

Related coverage

Reader discussion

Join the discussion. Every comment is checked before publication. Community rules and appeals